Discover the world of Recursive Self-Improvement (RSI) in AI. From I.J. Good's intelligence explosion to modern self-healing code and clinical applications, explore who is developing it, how it works, ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

Abstract: This article investigates the recursive state estimation problem for a class of nonlinear cyber-physical systems (CPSs) operating under a token bucket strategy regulated by a random access ...

June 10 (Reuters) - Recursion Pharmaceuticals (RXRX.O), opens new tab said on Tuesday it would lay off about 20% of its workforce as the biotech company tries to cope with an industry-wide funding ...

Recursion Pharmaceuticals announces a workforce reduction of approximately 20%. The Nvidia-backed company expects the move to extend its cash runway into the fourth quarter of 2027. Get more ...

Recursion said today it is eliminating approximately 20% of its workforce—about 160 jobs—in a restructuring the AI-based drug developer said reflects both its recently-pruned pipeline and the ...

I'll be brief. I need to be able to get 1 item from 2 sets of items and drop them together. Let's say there are 3 items in each set and we need to ensure that 1 item drops from the first set and 1 ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) fell this week. The stock lost 24% as of market close on Friday. The move comes as the S&P 500 and Nasdaq Composite both slipped slightly. Recursion ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes roughly ...